vs
CITIUS ONCOLOGY, INC.（CTOR）与Peraso Inc.（PRSO）财务数据对比。点击上方公司名可切换其他公司
CITIUS ONCOLOGY, INC.的季度营收约是Peraso Inc.的1.4倍（$3.9M vs $2.9M），Peraso Inc.净利率更高（-43.3% vs -140.3%，领先97.0%）
Citius Oncology是一家处于后期阶段的生物制药企业，专注于开发针对癌症患者的创新靶向疗法，核心管线覆盖血液恶性肿瘤和实体瘤领域的未满足医疗需求，主要服务北美及全球肿瘤诊疗市场。
Peraso Inc.是一家半导体技术企业，专注于设计和生产高性能毫米波（mmWave）集成电路与模块，为电信基础设施、工业物联网、固定无线接入及消费电子领域提供5G及下一代无线连接解决方案，服务全球多个地区的客户。
CTOR vs PRSO — 直观对比
营收规模更大
CTOR
是对方的1.4倍
$2.9M
净利率更高
PRSO
高出97.0%
-140.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.9M | $2.9M |
| 净利润 | $-5.5M | $-1.2M |
| 毛利率 | 80.0% | 52.2% |
| 营业利润率 | -133.2% | -44.6% |
| 净利率 | -140.3% | -43.3% |
| 营收同比 | — | -22.0% |
| 净利润同比 | 16.9% | 20.3% |
| 每股收益（稀释后） | $-0.06 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTORPRSO
| Q4 25 | $3.9M | $2.9M | ||
| Q3 25 | — | $3.2M | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | — | $3.9M | ||
| Q4 24 | — | $3.7M | ||
| Q3 24 | — | $3.8M | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $2.8M |
净利润CTORPRSO
| Q4 25 | $-5.5M | $-1.2M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $-471.0K | ||
| Q4 24 | — | $-1.6M | ||
| Q3 24 | — | $-2.7M | ||
| Q2 24 | — | $-4.4M | ||
| Q1 24 | — | $-2.0M |
毛利率CTORPRSO
| Q4 25 | 80.0% | 52.2% | ||
| Q3 25 | — | 56.2% | ||
| Q2 25 | — | 48.3% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 47.0% | ||
| Q2 24 | — | 55.5% | ||
| Q1 24 | — | 46.4% |
营业利润率CTORPRSO
| Q4 25 | -133.2% | -44.6% | ||
| Q3 25 | — | -36.8% | ||
| Q2 25 | — | -80.0% | ||
| Q1 25 | — | -13.3% | ||
| Q4 24 | — | -44.3% | ||
| Q3 24 | — | -70.3% | ||
| Q2 24 | — | -105.6% | ||
| Q1 24 | — | -128.9% |
净利率CTORPRSO
| Q4 25 | -140.3% | -43.3% | ||
| Q3 25 | — | -37.4% | ||
| Q2 25 | — | -82.4% | ||
| Q1 25 | — | -12.2% | ||
| Q4 24 | — | -42.4% | ||
| Q3 24 | — | -70.6% | ||
| Q2 24 | — | -104.4% | ||
| Q1 24 | — | -72.1% |
每股收益（稀释后）CTORPRSO
| Q4 25 | $-0.06 | $-0.09 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.31 | ||
| Q1 25 | — | $-0.10 | ||
| Q4 24 | — | $0.36 | ||
| Q3 24 | — | $-0.98 | ||
| Q2 24 | — | $-1.88 | ||
| Q1 24 | — | $-1.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.3M | $2.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $58.4M | $4.6M |
| 总资产 | $110.0M | $6.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTORPRSO
| Q4 25 | $7.3M | $2.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $2.4M |
股东权益CTORPRSO
| Q4 25 | $58.4M | $4.6M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $6.7M |
总资产CTORPRSO
| Q4 25 | $110.0M | $6.1M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | — | $5.5M | ||
| Q1 25 | — | $6.7M | ||
| Q4 24 | — | $7.2M | ||
| Q3 24 | — | $7.2M | ||
| Q2 24 | — | $9.8M | ||
| Q1 24 | — | $11.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-7.4M | $-1.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CTORPRSO
| Q4 25 | $-7.4M | $-1.1M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-966.0K | ||
| Q4 24 | — | $-687.0K | ||
| Q3 24 | — | $-683.0K | ||
| Q2 24 | — | $-659.0K | ||
| Q1 24 | — | $-2.5M |
自由现金流CTORPRSO
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率CTORPRSO
| Q4 25 | — | — | ||
| Q3 25 | — | -48.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度CTORPRSO
| Q4 25 | — | — | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTOR
暂无分部数据
PRSO
| Products | $2.8M | 96% |
| Other | $105.0K | 4% |
